Celcuity (CELC) Cash & Equivalents (2016 - 2026)
Celcuity's (CELC) quarterly Cash & Equivalents came in at $441.5 million in Q4 2025, up 1862.22% YoY from $22.5 million in Q4 2024, and up 494.6% on a QoQ basis from $74.3 million in Q3 2025.
Celcuity (CELC) Cash & Equivalents (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Cash & Equivalents data on file, last reported at $441.5 million in Q4 2025.
- Quarterly Cash & Equivalents rose 1862.22% year-over-year to $441.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $441.5 million (up 1862.22% YoY) and the FY2025 annual result came in at $441.5 million, up 1862.22% from the prior year.
- Cash & Equivalents advanced to $441.5 million in Q4 2025, from $74.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $441.5 million in Q4 2025 to a low of $12.6 million in Q3 2024.
- A 5-year average of $63.8 million and a median of $34.3 million in 2021 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 70.85% — and 2025, when it jumped 1862.22%.
- Tracing CELC's Cash & Equivalents over 5 years: stood at $84.3 million in 2021, then sank by 70.85% to $24.6 million in 2022, then grew by 24.79% to $30.7 million in 2023, then declined by 26.62% to $22.5 million in 2024, then jumped by 1862.22% to $441.5 million in 2025.
- The last three Cash & Equivalents figures came in at $441.5 million (Q4 2025), $74.3 million (Q3 2025), and $46.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | 754.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 754.00 Mn |
| Dec 31, 2025 | 441.50 Mn |
| Sep 30, 2025 | 74.25 Mn |
| Jun 30, 2025 | 46.35 Mn |
| Mar 31, 2025 | 16.48 Mn |
| Dec 31, 2024 | 22.50 Mn |
| Sep 30, 2024 | 12.60 Mn |
| Jun 30, 2024 | 30.46 Mn |
| Mar 31, 2024 | 31.21 Mn |
| Dec 31, 2023 | 30.66 Mn |
| Sep 30, 2023 | 25.76 Mn |
| Jun 30, 2023 | 32.24 Mn |
| Mar 31, 2023 | 33.64 Mn |
| Dec 31, 2022 | 24.57 Mn |
| Sep 30, 2022 | 57.48 Mn |
| Jun 30, 2022 | 66.91 Mn |
| Mar 31, 2022 | 78.30 Mn |
| Dec 31, 2021 | 84.29 Mn |
| Sep 30, 2021 | 90.37 Mn |
| Jun 30, 2021 | 41.64 Mn |